Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

How to optimize HCV therapy in genotype 2 patients.

Grassi E, Aghemo A.

Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056. Review.

PMID:
23286844
2.

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP.

Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067. Review.

PMID:
23286846
3.
4.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
5.

What's new in HCV genotype 2 treatment.

Mangia A, Mottola L.

Liver Int. 2012 Feb;32 Suppl 1:135-40. doi: 10.1111/j.1478-3231.2011.02710.x. Review.

PMID:
22212584
6.
8.

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2014 Apr;49(4):737-47. doi: 10.1007/s00535-013-0824-z. Epub 2013 May 21.

PMID:
23689988
9.

Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin.

Conti F, Vukotic R, Lorenzini S, Riili A, Cursaro C, Scuteri A, Loggi E, Galli S, Furlini G, Bernardi M, Andreone P.

Ann Hepatol. 2014 Mar-Apr;13(2):196-203.

10.

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.

Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, Orholm M, Ring-Larsen H, Bukh J, Krogsgaard K.

Scand J Gastroenterol. 2012 Sep;47(8-9):1115-9. doi: 10.3109/00365521.2012.694905. Epub 2012 Jun 7.

PMID:
22670704
11.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

12.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

13.

Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.

Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.

J Womens Health (Larchmt). 2015 Feb;24(2):159-64. doi: 10.1089/jwh.2014.4796. Epub 2015 Feb 3.

PMID:
25682817
14.

How to optimize HCV therapy in genotype 4 patients.

Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M.

Liver Int. 2013 Feb;33 Suppl 1:41-5. doi: 10.1111/liv.12059. Review.

PMID:
23286845
15.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
16.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
17.

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.

Gill U, Aziz H, Gill ML.

Int J Infect Dis. 2013 Nov;17(11):e1017-21. doi: 10.1016/j.ijid.2013.05.012. Epub 2013 Jul 27.

18.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Hepatology. 2008 Jun;47(6):1884-93. doi: 10.1002/hep.22319.

PMID:
18508296
19.

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.

Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G.

Scand J Gastroenterol. 2013 Jul;48(7):839-47. doi: 10.3109/00365521.2013.793389.

PMID:
23795661
20.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466

Supplemental Content

Support Center